Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Phase of Trial: Phase I/II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Nov 2018 Planned initiation date changed from 25 Oct 2018 to 25 Jan 2019.
- 17 Oct 2018 New trial record